Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Migraine Disorders
Interventions
onabotulinumtoxinA, Topiramate
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
32
States / cities
Phoenix, Arizona • Encinitas, California • Fresno, California + 28 more
Conditions
Adolescent Obesity, Obesity in Adolescence, Adolescent Overweight
Interventions
VI-0521 oral capsule, Placebo oral capsule, Lifestyle Modification
Drug · Behavioral
Lead sponsor
VIVUS LLC
Industry
Eligibility
12 Years to 16 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Norman, Oklahoma
Conditions
Obesity
Interventions
Comprehensive weight loss, Enhanced lifestyle changes, Phentermine-Topiramate, Naltrexone-Bupropion Combination, Orlistat
Other · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
25 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Idiopathic Parkinson's Disease, Drug Induced Dyskinesia
Interventions
Topiramate, Placebo, Amantadine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
30 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 2 more
Conditions
Chronic Migraine
Interventions
onabotulinumtoxinA, Topiramate, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Springfield, Missouri
Terminated Phase 3 Interventional Results available

Topiramate in the Treatment of Pathological Gambling

NCT00245583
Conditions
Pathological Gambling
Interventions
Topiramate, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Conditions
Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
Interventions
Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), Lifestyle Counseling - Diet & Physical-Activity Program
Procedure · Drug · Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Traumatic Brain Injury (TBI), Hazardous and Harmful Alcohol Use
Interventions
Medical Management Counseling, Topiramate, Placebo
Behavioral · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
San Francisco, California
Conditions
Obesity, Morbid, Bariatric Surgery, Adolescent, Young Adult, Drug Therapy
Interventions
Phentermine, Immediate Release Topiramate, Placebo for Phentermine, Placebo for Immediate Release Topiramate
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 24 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Epilepsy
Interventions
Topiramate, Levetiracetam
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 15 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Gulf Breeze, Florida + 9 more
Conditions
Cocaine Dependence
Interventions
Adderall-XR and Topiramate, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Conditions
Obesity
Interventions
VI-0521, topiramate, phentermine
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Conditions
Type 2 Diabetes Mellitus
Interventions
VI-0521, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Conditions
Obesity
Interventions
topiramate, phentermine
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Mountain View, California
Active, not recruiting No phase listed Observational

Weight Loss Management in Endometrial Cancer Survivors

NCT06877572
Conditions
Endometrial Cancer Survivors, Weight Management, Early Stage Endometrial Cancer
Interventions
Weight loss with pharmacotherapy, Weight loss without pharmacotherapy
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Healthy
Interventions
Topiramate Sprinkle Capsules 25 mg, Topamax® Sprinkle Capsules 25 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Morgantown, West Virginia
Conditions
Bipolar Disorder, Alcohol Abuse
Interventions
quetiapine and placebo, Quetiapine and Topiramate
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 25 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
PTSD
Interventions
topiramate
Drug
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Conditions
Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
Interventions
Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo
Drug · Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Years to 28 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Completed Phase 2Phase 3 Interventional Results available

Topiramate and Prolonged Exposure

NCT03176953
Conditions
PTSD and Alcohol Use Disorder
Interventions
topiramate, prolonged exposure, placebo
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
San Diego, California
Conditions
Migraine Disorders, Headache Disorders
Interventions
SPN-538, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission, Non-Hodgkin Lymphoma in Remission, Cancer Survivorship
Interventions
Phentermine/Topiramate ER, Health Behavior and Lifestyle Counseling
Drug · Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years to 24 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Completed Phase 3 Interventional Results available

Individualized Obesity Pharmacotherapy

NCT03374956
Conditions
Obesity
Interventions
Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion, Phentermine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Recruiting Not applicable Interventional Accepts healthy volunteers

Preoperative Weight Loss for Open Abdominal Wall Reconstruction

NCT05925959
Conditions
Abdominal Wall Hernia
Interventions
Preoperative Weight Management Program
Other
Lead sponsor
Benjamin T. Miller
Other
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Cleveland, Ohio